Detection of early-stage pancreatic adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 11, 2010, Pages 2786-2794

  Gold, David V ^a   Goggins, Michael ^b   Modrak, David E ^a   Newsome, Guy ^a   Liu, Mengling ^c   Shi, Chanjuan ^b   Hruban, Ralph H ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CHRONIC PANCREATITIS; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; EARLY DETECTION OF CANCER; HUMANS; IMMUNOENZYME TECHNIQUES; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78549263079     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0667     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Horner MJ, Ries LAG, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2006. Bethesda (MD): National Cancer Institute; 2009, http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER website.
3. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg 2007;246:173-80.
4. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994;57:204-10.
5. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007;13:7380-7.
6. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006;24:252-8.
7. Guidance for Industry Bioanalytical Method Validation. Rockville, MD: Food and Drug Administration, FDA publication UCM070107; 2001.
8. Slomiany A, Jozwiak Z, Takagi A, Slomiany BL. The role of covalently bound fatty acids in the degradation of human gastric mucus glycoprotein. Arch Biochem Biophys 1984;229:560-7.
9. Slomiany BL, Tsukada H, Slomiany A. Cotranslational attachment of fatty acids to nascent peptides in gastric mucus glycoprotein. Biochem Biophys Res Commun 1986;141:387-93.
10. Zalesna G, Tsukada H, Okazaki K, Slomiany BL, Slomiany A. Synthesis and initial processing of gastric apomucins. Biochem Int 1989;18:775-84.
11. Walter K, Hong SM, Nyhan S, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev 2009;19:2380-5.
12. Leach SD. Mouse models of pancreatic cancer; the fur is finally flying! Cancer Cell 2004;5:7-11.
13. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 2007;171:263-73.
14. Shi C, Hong SM, Lim P, et al. Kras2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res 2009;7:230-6.
15. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-81.
16. Canto MI. Screening for pancreatic neoplasia in high-risk individuals: who, what, when, how? Clin Gastroenterol Hepatol 2005;3:S46-8.
17. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-55.
18. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009;133:365-74.
19. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 2002;62:3789-93.
20. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
21. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:342-6.
22. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
23. Tischkowitz MD, Sabbaghian N, Hamel N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009;137:1183-6.
24. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010, Epub ahead of print.
25. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-7.
26. Lowenfels AB, Maisonneuve P, DiMagno EP, et al, International Hereditary Pancreatitis Study Group. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997;89:442-6.
27. Rutter JL, Bromley CM, Goldstein AM, et al. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer 2004;101:2809-16.
28. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
29. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504-11.
30. Mariani G, Molea N, Bacciardi D, et al. Initial targeting, biodistribution and pharmacokinetics screening of the monoclonal antibody PAM4 for immunoscintigraphy in patients with pancreatic cancer. Cancer Res 1995;55:5911-5s.
31. Gold DV, Cardillo T, Goldenberg DM, Sharkey RM. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit Rev Oncol Hematol 2001;39:147-54.
32. Cardillo TM, Karacay H, Goldenberg DM, et al. Improved targeting of pancreatic cancer: Experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res 2004;10:3552-61.
33. Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic adenocarcinoma. Cancer Res 2008;68:4819-26.
34. Pennington K, Guarino MJ, Serafini AN, et al. Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer. J Clin Oncol 2009;27:15s, (suppl; abstract 4620).
35. Gold DV, Newsome G, Modrak DE, et al. PAM4-antigen levels in the serum of patients with pancreatic carcinoma: early detection of disease and correlation with responses to radioimmunotherapy. Proc Annual Meeting of the AACR; 2010 April 17-21, Washington (DC). 2010. (abstract 4622).